CD8 + T cell response to human papillomavirus 16 E7 is able to predict survival outcome in oropharyngeal cancer

Masterson, Liam; Lechner, Matt; Loewenbein, Sarah; Hassan, Md. Imtaiyaz; Davies-Husband, C R; Fenton, Tim R.; Sudhoff, Holger; Jani, Piyush; Goon, Peter; Sterling, Jane

doi:10.1016/j.ejca.2016.08.012

Cited by 54 publications

(52 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the better prognosis and treatment outcomes could be attributed to other factors. Factors like immune surveillance of virus-specific tumor antigens, like high CD8þ T-cell infiltration, and lack of field cancerization may contribute to the better treatment outcome of HPV-positive OPSCC's overall survival and prognosis [36][37][38][39]. Further, one study found that HPV-positive tumors were not correlated with perineural invasion (PNI) or perivascular invasion (PVI), which have been reported as independent predictors of poor survival [40].…”

Section: Discussionmentioning

confidence: 99%

Rate of locoregional recurrence among patients with oropharyngeal squamous cell carcinoma with known HPV status: a systematic review

et al. 2020

View full text Add to dashboard Cite

Background: We aimed to review systematically the literature on locoregional recurrence rates in patients with HPV-positive and-negative oropharyngeal squamous cell carcinoma (OPSCC). Methods: PubMed and Embase databases were systematically searched using key words such as human papillomavirus, oropharyngeal squamous cell carcinoma with local, regional, and locoregional recurrence. Results: Nine studies (2974 patients with known HPV-status, 59% HPV-positive) were included. Among the HPV-positive and-negative patients, 69% and 58% had lymph node metastasis at diagnosis. At a median time to recurrence ranging from 8.4 to 13.2 months among the included studies, we found that a weighted average of 9% and 26% for HPV-positive and-negative patients experienced locoregional recurrence. Overall, the median follow-up time ranged from 21 to 83 months among the included studies. Conclusion: Recurrence rates for HPV-positive and-negative OPSCC patients were 9% and 26%, respectively, equating to an almost three times higher rate of locoregional recurrence among HPVnegative patients compared to HPV-positive patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Rate of locoregional recurrence among patients with oropharyngeal squamous cell carcinoma with known HPV status: a systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…As demonstrated here, immunization with adjuvanted gDE7 induced strong antitumor protection and promoted the activation of a DC population specifically involved with antigen cross-presentation and activation of CD8 þ T cells. Recent studies report that the priming of specific T-cell responses occurs in different HPV-induced cancer patients, including cervical cancer (46), head and neck (47), and oropharyngeal squamous cell carcinoma (48). Nonetheless, an effective tumor control requires adequate immunologic stimuli that could afford the concomitant activation of cytotoxic responses and control of tumor-induced immunosuppressive mechanisms.…”

Section: Discussionmentioning

confidence: 99%

Herpes Simplex Virus Glycoprotein D Targets a Specific Dendritic Cell Subset and Improves the Performance of Vaccines to Human Papillomavirus-Associated Tumors

Porchia

Moreno

Ramos

et al. 2017

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Cervical cancer is a major public health problem and one of the leading causes of cancer deaths in women. Virtually all cases of cervical cancer, as well as a growing share of anal and head/neck tumors, are associated with human papillomavirus (HPV) infection. Despite the effectiveness, the available prophylactic vaccines do not benefit women with cervical lesions or cancer. Therefore, the search of new immunotherapeutic approaches to treat HPV-induced tumors is still a priority. The present study characterizes a therapeutic antitumor vaccine based on the genetic fusion of the Herpes simplex virus-1 (HSV-1) glycoprotein D (gD) with the E7 oncoprotein from HPV-16 (gDE7). Two subcutaneous doses of gDE7, admixed with poly (I:C), conferred complete and long-lasting therapeutic antitumor protection on mice previously challenged with tumor cells expressing the HPV-16 oncoproteins. The vaccine induced multifunctional E7-specific CD8 T cells with cytotoxic activity and effector memory phenotype (CD44 CD62L). In addition, gDE7 admixed with poly (I:C) vaccination controlled the expansion of tumor-induced regulatory T cells and myeloid-derived suppressor cells. More importantly, gDE7 activated mouse CD11c CD8α and human BDCA3 dendritic cells (DC), specialized in antigen cross-presentation to CD8 T cells, under conditions. These results indicated that the activation of a specific DC population, mediated by gD, improved the antigen-specific immune responses and the therapeutic performance induced by antitumor vaccines. These results open perspectives for the clinical testing of gDE7-based vaccines under the concept of active immunization as a tool for the therapeutic control of cancer..

show abstract

“…However, these same E7‐specific cytotoxic T cells were unable to recognize an HLA‐A*201 expressing HPV+ tumor cell line and no studies have yet definitively identified the antigens within the tumor that trigger this host response. Moreover, CD8+ TIL function may have an impact on response to therapy as studies have shown improved disease‐free survival with retained or enhanced CD8+ activity in patients treated with radiotherapy +/− chemotherapy . Future interventions directed at increasing immune reactive CD8+ cytotoxic T cells may be beneficial in treatment of HPV‐associated OPSCC.…”

Section: Role Of Adaptive Immunity In Hpv‐positive Opsccmentioning

confidence: 99%

The role of the innate and adaptive immune response in HPV‐associated oropharyngeal squamous cell carcinoma

Subbarayan

Arnold

Gomez

et al. 2019

Laryngoscope Investig Oto

View full text Add to dashboard Cite

Human papilloma virus (HPV) has been implicated in the development of oropharyngeal squamous cell carcinoma (OPSCC) and is directly attributed to its increasing incidence. The immune microenvironment surrounding HPV‐associated OPSCC tumors is complex and plays a critical role in the carcinogenic process. The neoplastic mechanism includes cells of the innate immunity such as macrophages, and dendritic cells as well as cells of the adaptive immune process such as CD8+ T‐cells. The intricate interactions between these two arms of the immune system allow for a pro‐inflammatory and pro‐tumorigenic environment. Intensive efforts are underway to gain a greater understanding of the mechanisms involved in the immune system's role in tumor development. This study seeks to summarize the current knowledge pertaining to role of the innate and adaptive immune response in HPV‐associated OPSCC. Level of Evidence 3a

show abstract

CD8 + T cell response to human papillomavirus 16 E7 is able to predict survival outcome in oropharyngeal cancer

Cited by 54 publications

References 60 publications

Rate of locoregional recurrence among patients with oropharyngeal squamous cell carcinoma with known HPV status: a systematic review

Rate of locoregional recurrence among patients with oropharyngeal squamous cell carcinoma with known HPV status: a systematic review

Herpes Simplex Virus Glycoprotein D Targets a Specific Dendritic Cell Subset and Improves the Performance of Vaccines to Human Papillomavirus-Associated Tumors

The role of the innate and adaptive immune response in HPV‐associated oropharyngeal squamous cell carcinoma

Contact Info

Product

Resources

About